review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1002/14651858.CD007578.PUB2 |
P698 | PubMed publication ID | 21412905 |
P2093 | author name string | Michael Taylor | |
Rebecca Ryan | |||
Kelly Allen | |||
Sophie Hill | |||
Cathy Mead | |||
Dianne Lowe | |||
P2860 | cites work | Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) through medical treatment (iatrogenically) | Q24242392 |
Methods of communicating a primary diagnosis of breast cancer to patients | Q24244055 | ||
Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US | Q24288772 | ||
The reporting of theoretical health risks by the media: Canadian newspaper reporting of potential blood transmission of Creutzfeldt-Jakob disease | Q24807265 | ||
Methods for the thematic synthesis of qualitative research in systematic reviews | Q29618082 | ||
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings | Q29619731 | ||
Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard? | Q30230440 | ||
Variant Creutzfeldt-Jakob disease: a cause for concern. Review of the evidence for risk of transmission through abdominal lymphoreticular tissue surgery. | Q31168115 | ||
The expanding universe of prion diseases | Q33239695 | ||
Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002. | Q33263263 | ||
Methods for the synthesis of qualitative research: a critical review | Q33492573 | ||
Variant Creutzfeldt Jakob Disease | Q34056300 | ||
Creutzfeldt-Jakob disease: the problem of recipient notification | Q34077606 | ||
Creutzfeldt-Jakob disease: blood infectivity and screening tests | Q34422601 | ||
Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies | Q34489473 | ||
Ethical analysis of communicating the risk of iatrogenic Creutzfeldt-Jakob disease | Q49134178 | ||
The mad cow problem in the UK: risk perceptions, risk management, and health policy development. | Q50161938 | ||
Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion | Q50193994 | ||
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. | Q51037857 | ||
An investigation of potential neurosurgical transmission of Creutzfeldt-Jakob disease: challenges and lessons learned. | Q51249039 | ||
Problems with disposable laryngoscope blades. | Q51302622 | ||
Collaborative infection control policies for anaesthetic equipment are needed. | Q51341139 | ||
Risk factors for sporadic Creutzfeldt-Jakob disease. | Q53031206 | ||
An innovative, inclusive process for meso-level health policy development. | Q53180859 | ||
Intersecting discourses: MMR vaccine and BSE. | Q53292756 | ||
British MRC reprimanded over clinical test record. | Q53573513 | ||
Prion diseases and dental treatment: principles and practice of patients with/suspected or at-risk of CJD: case reports. | Q53916657 | ||
The HIV information project for transfusion recipients a decade after transfusion. | Q54598459 | ||
Peer-Reviewed Articles and Public Health | Q56346039 | ||
Uncertainty and significance | Q57112490 | ||
From alcohol and breast cancer to beef and BSE--improving our communication of risk | Q57241670 | ||
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy | Q57301966 | ||
BSE in human tissue fires debate on patient disclosure | Q59032179 | ||
Consensus conference on vCJD screening of blood donors: report of the panel | Q59465666 | ||
Brussels inquiry criticizes BSE secrecy | Q60089074 | ||
Quarterly communicable disease review. April to June 2001. | Q34549531 | ||
The prion theory: background and basic information | Q34582147 | ||
Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives | Q34636936 | ||
The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test | Q34680311 | ||
Mechanical design of a shape memory alloy actuated prosthetic hand | Q34704724 | ||
Sterilization issues in vCJD--towards a consensus: meeting between the Central Sterilizing Club and Hospital Infection Society. 12th September 2000. | Q34812377 | ||
Desired elements of HIV testing services: test recipient perspectives | Q35039273 | ||
Communication, information and support for adults with malignant cerebral glioma : a systematic literature review | Q35045010 | ||
How to formulate research recommendations | Q35082894 | ||
Risk communication of the transmissible spongiform encephalopathies | Q35148252 | ||
Ethical considerations in presymptomatic testing for variant CJD. | Q35428275 | ||
Acquired prion disease: iatrogenic CJD, variant CJD, kuru | Q35549020 | ||
vCJD screening and its implications for transfusion - strategies for the future? | Q35563651 | ||
Managing recalls and withdrawals of blood components | Q35613182 | ||
A review of general hepatitis C virus lookbacks in Canada | Q35675883 | ||
Creutzfeldt-Jakob disease following corneal transplantation | Q35751022 | ||
Informed consent for blood transfusion: should the possibility of prion risk be included? | Q35833537 | ||
Communicating with patients about medical errors: a review of the literature | Q35859667 | ||
Joint ASH and AABB educational session | Q35961850 | ||
Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination | Q36037149 | ||
How can doctors communicate information about risk more effectively? | Q36037213 | ||
Mad cow disease and vCJD: understanding the risks | Q36038404 | ||
Care management of Creutzfeldt-Jakob Disease within the United Kingdom | Q36048676 | ||
No clinical evidence of hidden vCJD in UK children | Q36153081 | ||
Communicating prognosis in cancer care: a systematic review of the literature | Q36154086 | ||
Developing an administrative plan for transfusion medicine--a global perspective | Q36266564 | ||
Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty. | Q36302930 | ||
Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience | Q36381542 | ||
Discussing bad news in the outpatient oncology clinic: rethinking current communication guidelines | Q36381835 | ||
A patient's perspective on hemophilia | Q36456673 | ||
Public health and civil liberties. Introduction to the talking point on public health versus civil liberties | Q36495086 | ||
Creutzfeldt-Jakob disease: a rare cause of dementia in elderly persons | Q36521408 | ||
Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study | Q36588347 | ||
Decontamination and CJD: the latest guidance | Q36670760 | ||
Empty systematic reviews: hidden perils and lessons learned | Q36817449 | ||
Response to paper by Lang A, Edwards N, and Fleiszer A. | Q36817453 | ||
Halting the spread of human prion disease--exceptional measures for an exceptional problem | Q36836191 | ||
The epidemiology of Creutzfeldt-Jakob disease in Canada: a review of mortality data | Q36857133 | ||
An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products | Q37307945 | ||
What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare. | Q37332504 | ||
Breaking bad news. 2: What evidence is available to guide clinicians? | Q38550704 | ||
Science, uncertainty and policy: food for thought | Q38703116 | ||
Public understanding of food risks in four European countries: a qualitative study | Q39032058 | ||
Is surgery a risk factor for Creutzfeldt-Jakob disease? Outcome variation by control choice and exposure assessments | Q40126129 | ||
Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. | Q40305663 | ||
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. | Q40483672 | ||
Future counselling of donors and recipients of blood products concerning prion-related diseases | Q40567812 | ||
Knowledge, attitude, and behavior of students regarding 'mad cow disease'. | Q40573579 | ||
Creutzfeldt-Jakob disease and infection control | Q40664868 | ||
Health communication and consumer behavior on meat in Belgium: from BSE until dioxin | Q40767195 | ||
Surveillance of blood transfusion safety: contribution of the hemovigilance strategy in France | Q41753407 | ||
Patients informed of increased risk of vCJD contact | Q42404954 | ||
A new human genotype prone to variant Creutzfeldt-Jakob disease | Q42530495 | ||
Monitoring Creutzfeldt-Jakob disease | Q42763284 | ||
Victims of Creutzfeldt-Jakob disease | Q42763739 | ||
The politics of risk: the case of BSE. If we want less paternalism we must first educate ourselves | Q42769043 | ||
Communicating risks | Q42948885 | ||
Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992. | Q43035681 | ||
Recipients of blood or blood products "at vCJD risk". | Q43124338 | ||
Creutzfeldt-Jakob disease after pituitary gonadotrophins | Q43152098 | ||
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy... but members of the public make up their own minds about risks | Q43180220 | ||
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Scientists who inflame public anxieties must share responsibility for resulting panic | Q43187765 | ||
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Doctors and scientists must be able to communicate degree of risk... | Q43187789 | ||
Bovine spongiform encephalopathy. Study shows need for better communication between government and doctors | Q43190287 | ||
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada | Q43218822 | ||
International case studies of psychosocial ripple effects of bovine spongiform encephalopathy (BSE) in European countries | Q43565202 | ||
Policy understanding of science, public trust and the BSE-CJD crisis. | Q44011663 | ||
Good and bad news about transmissible spongiform encephalopathies (prion diseases). | Q44068517 | ||
Creutzfeld-Jakob disease: recommendations for infection control. | Q44921979 | ||
Prions and haemophilia: assessment of risk | Q45855088 | ||
Dental treatment of a patient in the new 'at-risk' category for CJD. | Q45875887 | ||
Genomics and blood substitutes for 21st century Europe ("EuroBloodSubstitutes"). | Q46773050 | ||
Proceedings of a consensus conference: the screening of blood donors for variant CJD. | Q47808189 | ||
Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. | Q48340913 | ||
The spongiform encephalopathies: prion diseases. | Q48350306 | ||
Transplantation of ocular tissue from a donor with sporadic Creutzfeldt-Jakob disease | Q48422321 | ||
"On a supposed right to lie [to the public] from benevolent motives": communicating health risks to the public | Q48686947 | ||
Percutaneous tracheostomy and Creutzfeldt-Jakob Disease | Q48875709 | ||
Some ethical ground rules for BSE and other public health threats | Q48933321 | ||
Bovine spongiform encephalopathy (BSE): the ethics concerning decisions about whether to continue taking a risk with this disease | Q48933332 | ||
Blood contamination of the laryngeal mask airways and laryngoscopes--what do we tell our patients? | Q49125256 | ||
BSE meeting reflects growing distrust of expert panels | Q60089325 | ||
Patients' and family members' experiences of open disclosure following adverse events | Q60806370 | ||
Listening to patients with rare diseases | Q64043947 | ||
Bovine Spongiform Encephalopathy and Related Agents: Risk Factors of Biological Products. An Informal Consultation/Working Meeting | Q68331192 | ||
Creutzfeldt-Jakob disease | Q70811575 | ||
Getting the message across | Q71286418 | ||
Pooled plasma derivatives and Creutzfeldt-Jakob disease | Q71520229 | ||
Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study | Q73176027 | ||
Creutzfeldt-Jakob disease and eye surgery--new disease, old disease | Q73245965 | ||
The BSE inquiry and communication of risk | Q73478341 | ||
BSE report | Q73519221 | ||
vCJD: broad U.S. response required | Q73602250 | ||
Breaking bad news about cancer: patients' preferences for communication | Q73703066 | ||
Transfusion medicine and spongiform encephalopathy | Q73794148 | ||
Controlling new prion diseases | Q73890310 | ||
[The precaution principle and blood transfusion] | Q74086100 | ||
Department of Health withdraws variant CJD transmission recommendations for single-use instruments | Q74218887 | ||
United Nations address | Q74286892 | ||
Prevention of Creutzfeldt-Jakob disease in health care workers: a case study | Q74315452 | ||
CJD update | Q74336288 | ||
Communication of risk: choice, consent, and trust | Q74484476 | ||
Infectious diseases. First U.S. case of mad cow sharpens debate over testing | Q75236334 | ||
[Development of public health law: valuable elements worth sharing] | Q76323444 | ||
[A screening questionnaire for determining risk of Creuzfeldt-Jacob disease transmission during ophthalmic examination] | Q76341769 | ||
Potential Creutzfeldt-Jakob disease (CJD) exposure: to notify or not to notify | Q77141810 | ||
Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART). Quantification of risks as part of informed consent | Q77309520 | ||
Hepatitis C update: implications of the blood transfusion "lookback" | Q77400968 | ||
Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies | Q77738553 | ||
Creutzfeldt-Jakob disease targeted lookback | Q77770301 | ||
HIV Testing And Counseling: Test Providers' Experiences of Best Practices | Q79094523 | ||
The CJD mystery | Q79131508 | ||
Variant Creutzfeldt-Jacob disease - the availability of a screening test will be the beginning, not the end, of difficult transfusion-related issues | Q79279401 | ||
[Transfusion risk analysis with regard to vCJD in France] | Q79450767 | ||
Implications of notifying donors and recipients | Q80226808 | ||
Long-term survival after blood transfusion: a population based study in the North of England | Q80260178 | ||
Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features | Q80508289 | ||
French doctors on trial for manslaughter | Q80773835 | ||
6 Years of shot reporting--its influence on UK blood safety | Q80900269 | ||
Informed consent for creutzfeldt-jakob disease after corneal transplantation | Q81158992 | ||
Fighting the good fight in Europe | Q81180265 | ||
Questionnaire to reduce the risk of iatrogenic prion disease transmission | Q81819380 | ||
Disclosing medical errors to patients: a challenge for health care professionals and institutions | Q84409392 | ||
Minerva | Q93606658 | ||
Variant Creutzfeldt-Jakob disease: costs borne by families | Q95801859 | ||
The HRT story: lessons for epidemiologists | Q95814736 | ||
P921 | main subject | prion protein family | Q24724413 |
Creutzfeldt-Jakob disease | Q49989 | ||
P577 | publication date | 2011-03-16 | |
P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
P1476 | title | Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically) |